Stabilization Algorithm

Similar documents
APPENDIX 7 CLINICAL INSTITUTE NARCOTIC ASSESSMENT (CINA) SCALE FOR WITHDRAWAL SYMPTOMS

CMBHS Clinical Management of Behavioral Health Services

Alcohol withdrawal. Clinical features

ALCOHOL WITHDRAWAL GUIDELINES

Taking the pain out of prescribing: An opioid primer for the primary care provider

Assessment Main title and management of alcohol dependence and withdrawal in the acute hospital: concise guidance

Initial Patient Assessment Form To be filled out by patient Joseph Park, M.D., F.R.C.P.(C) Anesthesiology & Pain Management

PPT-PGN-26 Part of NTW(C)38-Pharmacological therapies

Lead for Gastroenterology Lee Dodge Alcohol Liaison 03/03/2015. Clive Gibson Safeguarding Adults Lead Nurse 03/03/2015

Lorraine Wilson, 74 years of age, is admitted. Alcohol Withdrawal. During Hospitalization. Early recognition and consistent intervention are critical.

Recovery Reintegration. Substance Use Disorder. Resilience. Reintegration. Recovery

Guidelines for Community Detoxification using Buprenorphine.

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Withdrawal.

Alcohol Withdrawal Guidelines

MEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP

MEDICATION GUIDE Morphine Sulfate (mor-pheen) (CII) Oral Solution

MEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution

Title Alcohol Withdrawal Management Guidelines

Medical Issues for counselors, copy for AATOD conference. In press, Journal of Maintenance in the Addictions Page 1 of 8

Admit date: 1-WM 2-WM 3.2-WM 3.7-WM 4-WM DSM-V diagnoses: Please list all diagnoses (psychiatric, chemical dependency and medical)

Anxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

What is the most important information I should know about Morphine Sulfate Oral Solution?

Anxiolytic & Hypnotic Drugs. Asst Prof Dr Inam S Arif

MEDICATION GUIDE MORPHINE Sulfate Oral Solution (mor-pheen) CII Rx only

Soma (carisoprodol), Soma Compound (carisoprodol and aspirin), Soma Compound w/ Codeine (carisoprodol and aspirin and codeine)

Alcohol withdrawal including the Symptom triggered CIWA score Management

Soma (carisoprodol), Soma Compound (carisoprodol and aspirin), Soma Compound w/ Codeine (carisoprodol and aspirin and codeine)

11/1/2010. Psychology 472 Pharmacology of Psychoactive Drugs. Listen to the audio lecture while viewing these slides

Dr Laith M Abbas Al-Huseini M.B.Ch.B, M.Sc., M.Res., Ph.D.

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT

MANAGEMENT AND DETOXIFICATION FOR GAMMA- HYDROXYBUTYRATE (GHB) AND GAMMA-BUTARYL LACTONE (GBL) GUIDELINES SEPTEMBER 2017

ALCOHOL USE DISORDER. Lada Alexeenko, MD

The Limits of Harm Reduction? Neil McKeganey Centre for Substance Use Research West of Scotland Science Park Glasgow Scotland

Headache Follow-up Visit Form

Methotrexate. About This Drug. Possible Side Effects. Warnings and Precautions

Northern Ireland Alcohol Use Disorders Care Pathway. management in the acute hospital setting

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.

Medical Necessity Criteria 2017

WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS

Tranquilizers & Sedative-Hypnotics

Opioid Addiction: Hospital Presentations and Management

*521634* Sleep History Questionnaire. Name of primary care doctor:

Provincial Clinical Knowledge Topic Alcohol Withdrawal, Adult Inpatient V 1.0

PATIENT INFORMATION LEAFLET SINTAIR RANGE

Benzodiazepines: Comparative Effectiveness and Strategies for Discontinuation. Ann M. Hamer, PharmD, BCPP Rural Oregon Academic Detailing Project

Anxiety Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM

SECTION 10: MANAGEMENT OF ALCOHOL, OPIOID AND BENZODIAZEPINE DEPENDENCE. Formulary and Prescribing Guidelines

MEDICATION GUIDE CODEINE SULFATE (koh-deen) CII Oral Solution

Behavioral Health Service Request Form Detox and Substance Abuse Rehab

Nivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan

Northern Ireland Alcohol Use Disorders Care Pathway. management in the acute hospital setting

Emotional Relationships Social Life Sexually Recreation

MEDICALLY ASSISTED COMMUNITY ALCOHOL WITHDRAWAL GUIDELINES SEPTEMBER 2015

Non-prescription Drugs. Wasted Youth

HEADACHE MEDICINE NEW PATIENT QUESTIONNAIRE

SEDATIVE-HYPNOTIC AGENTS

COUPLE & FAMILY INSTITUTE OF TRI-CITIES AMEN ADULT GENERAL SYMPTOM CHECKLIST

Questionnaire for Lipedema Patients

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan

PATIENT INFORMATION LEAFLET CARZIN XL

Anxiolytic and Hypnotic drugs

CENTRAL CARE POLICY SYMPTOMS OF ILLNESS. Policy: Consumers will be observed for symptoms of physical problems, distress, pain, or unusual behaviors.

Behavioral Health Service Request Form Detox and Substance Abuse Rehab

Safe and Effective Medication Approaches for Anxiety and Insomnia

Sedative / Hypnotics

Medical condition SELF Mother Father Sibling (list brother or sister) Anxiety Bipolar disorder Heart Disease Depression Diabetes High Cholesterol

Southeastern Rehabilitation Medicine Initial (New) Outpatient Information Questionnaire

Problem Summary. * 1. Name

Amarillo Surgical Group Doctor: Date:

Drug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment

Patient Information Montelukast Sodium Tablets and Montelukast Sodium Chewable Tablets

SECTION OF NEUROSURGERY PATIENT INFORMATION SHEET

DRUGS THAT ACT IN THE CNS

Methodist Hospital Alcohol Withdrawal Suggested Guidelines

MEDICATION GUIDE. BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use

Controlled Substance and Wellness Agreement

Overview of Psychoactive Drug use

Understanding Mental Illness A Review of the Disorders

Medical Interview 101

General Symptoms. Cold Weather Symptoms TG-272

ANTI-DEPRESSANT MEDICATIONS

Psychotropic Medication Use in Dementia

Behavioral Health Service Request Form Detox and Substance Abuse Rehab

Elements for a public summary

HISTORY OF PRESENT ILLNESS A. TELL US ABOUT YOUR PAIN PROBLEM

Behavioral Health Service Request Form Detox and Substance Abuse Rehab

NALOREX 50mg Film Coated Tablets (Naltrexone Hydrochloride)

Pain. Fear can keep the patient from going to the Drs at appropriate time

Emory Clinic Department of Neurological Surgery Second Opinion Questionnaire

Valium for stomach pain

Contents. May 2016 KYN Long Training 2

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)

VCU CENTER FOR SLEEP MEDICINE NEW PATIENT QUESTIONNAIRE

High Risk Medications. University of Illinois at Chicago College of Nursing

37 South 2 nd East, Rexburg, ID

Withdrawal Why is stopping substance use so difficult?

Complicated Withdrawal

Tiredness/Fatigue Mild Moderate to severe, especially at onset of symptoms Head and Body Aches and Pains

Transcription:

VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders Stabilization Algorithm Stabilization Pocket Card 1

Patient and Time Information Clinical Institute Withdrawal Assessment of Alcohol (CIWA-Ar) Name, date, time, pulse or heart rate taken for one minute, and blood pressure Items Nausea and vomiting: Ask, "Do you feel sick to your stomach? Have you vomited?" Observation. 0: No nausea and no vomiting 1: Mild nausea with no vomiting 4: Intermittent nausea with dry heaves 7: Constant nausea, frequent dry heaves and vomiting Tremor: Arms extended and fingers spread apart. Observation. 0: No tremor 1: Not visible, but can be felt fingertip to fingertip 4: Moderate, with patient's arms extended 7: Severe, even with arms not extended Paroxysmal sweats: Observation. 0: No sweat visible 1: Barely perceptible sweating, palms moist 4: Beads of sweat obvious on forehead 7: Drenching sweats Tactile disturbances: Ask, "Have you had any itching, pins and needles sensations, any burning, any numbness, or do you feel bugs crawling on or under your skin?" Observation. 0: None 1: Very mild itching, pins and needles, burning or numbness : Mild itching, pins and needles, burning or numbness : Moderate itching, pins and needles, burning or numbness 4: Moderately severe hallucinations : Severe hallucinations : Extremely severe hallucinations 7: Continuous hallucinations Auditory disturbances: Ask, "Are you more aware of sounds around you? Are they harsh? Do they frighten you? Are you hearing anything that is disturbing to you? Are you hearing things you know are not there?" Observation. 1: Very mild harshness or ability to frighten : Mild harshness or ability to frighten : Moderate harshness or ability to frighten 4: Moderately severe hallucinations : Severe hallucinations : Extremely severe hallucinations 7: Continuous hallucinations Visual disturbances: Ask, "Does the light appear to be too bright? Is its color different? Does it hurt your eyes? Are you seeing anything that is disturbing to you? Are you seeing things you know are not there?" Observation. 1: Very mild sensitivity : Mild sensitivity : Moderate sensitivity 4: Moderately severe hallucinations : Severe hallucinations : Extremely severe hallucinations 7: Continuous hallucinations

Clinical Institute Withdrawal Assessment of Alcohol (CIWA-Ar) Anxiety: Ask, "Do you feel nervous?" Observation. 0: No anxiety, at ease 1: Mild anxious 4: Moderately anxious, or guarded, so anxiety is inferred 7: Equivalent to acute panic states as seen in severe delirium or acute schizophrenic reactions Agitation: Observation. 0: Normal activity 1: Somewhat more than normal activity 4: Moderately fidgety and restless 7: Paces back and forth during most of the interview, or constantly thrashes about Scoring Total CIWA-Ar Score Rater's Initials Maximum Possible Score: 7 Headache, fullness in head: Ask, "Does your head feel different? Does it feel like there is a band around your head?" Do not rate for dizziness or lightheadedness. Otherwise, rate severity. 1: Very mild : Mild : Moderate 4: Moderately severe : Severe : Very severe 7: Extremely severe Orientation and clouding of sensorium: Ask, "What day is this? Where are you? Who am I?" 0: Oriented and can do serial additions 1: Cannot do serial additions or is uncertain about date : Disoriented for date by no more than calendar days : Disoriented for date by more than calendar days 4: Disoriented for place/or person Interpret sum of total scores as follows: Minimal or absent withdrawal: 9 Mild to moderate withdrawal: 10-19 Severe withdrawal: 0

Patient and Time Information Name, date, time, reason for this assessment Clinical Opiate Withdrawal Scale (COWS) Items Pulse Rate: Record Beats per Minute Measured after patient is sitting or lying for one minute 0: Pulse rate 80 or below 1: Pulse rate 81-100 : Pulse rate 101-10 4: Pulse rate greater than 10 Sweating: Over Past 1/ Hour not Accounted for by Room Temperature or Patient Activity 0: No report of chills or flushing 1: Subjective report of chills or flushing : Flushed or observable moistness on face : Beads of sweat on brow or face 4: Sweat streaming off face Restlessness Observation During Assessment 0: Able to sit still 1: Reports difficulty sitting still, but is able to do so : Frequent shifting or extraneous movements of legs/arms : Unable to sit still for more than a few seconds Pupil Size 0: Pupils pinned or normal size for room light 1: Pupils possibly larger than normal for room light : Pupils moderately dilated : Pupils so dilated that only the rim of the iris is visible Bone or Joint Aches if Patient was Having Pain Previously, only the Additional Component Attributed to Opiate Withdrawal is Scored 1: Mild diffuse discomfort : Patient reports severe diffuse aching of joints/muscles 4: Patient is rubbing joints or muscles and is unable to sit still because of discomfort Runny Nose or Tearing Not Accounted for by Cold Symptoms or Allergies 1: Nasal stuffiness or unusually moist eyes : Nose running or tearing 4: Nose constantly running or tears streaming down cheeks Gastrointestinal Upset: Over Last 1/ Hour 0: No gastrointestinal symptoms 1: Stomach cramps : Nausea or loose stool : Vomiting or diarrhea : Multiple episodes of diarrhea or vomiting Tremor Observation of Outstretched Hands 0: No tremor 1: Tremor can be felt, but not observed : Slight tremor observable 4: Gross tremor or muscle twitching Yawning Observation During Assessment 0: No yawning 1: Yawning once or twice during assessment : Yawning three or more times during assessment 4: Yawning several times/minute Anxiety or Irritability 0: None 1: Patient reports increasing irritability or anxiousness : Patient obviously irritable/anxious 4: Patient so irritable or anxious that participation in the assessment is difficult Gooseflesh Skin 0: Skin is smooth : Piloerection of skin can be felt or hairs standing up on arms : Prominent piloerection 4

Scoring Total COWS Score Rater's Initials Maximum Possible Score: 48 Clinical Opiate Withdrawal Scale (COWS) Interpret sum of total scores as follows: Mild withdrawal: -1 Moderate withdrawal: 1-4 Moderately severe withdrawal: - Severe withdrawal: > Patients Appropriate for Inpatient Medically Supervised Withdrawal Management Patients for Whom Inpatient Medically Supervised Withdrawal Management is Recommended Patients with any of the following conditions: History of delirium tremens or withdrawal seizures Inability to tolerate oral medication Co-occurring medical conditions that would pose serious risk for ambulatory withdrawal management (e.g., severe coronary artery disease, congestive heart failure, liver cirrhosis) Severe alcohol withdrawal (i.e., CIWA-Ar score 0) Risk of withdrawal from other substances in addition to alcohol (e.g., sedative hypnotics) Abbreviation: CIWA-Ar: Clinical Institute Withdrawal Assessment for Alcohol (revised version) Patients for Whom Inpatient Medically Supervised Withdrawal Management is Suggested Patients with at least moderate alcohol withdrawal (i.e., CIWA-Ar score 10 and any of the following conditions: Recurrent unsuccessful attempts at ambulatory withdrawal management Reasonable likelihood that the patient will not complete ambulatory withdrawal management (e.g., due to homelessness) Active psychosis or severe cognitive impairment Medical conditions that could make ambulatory withdrawal management problematic (e.g., pregnancy, nephrotic syndrome, cardiovascular disease, lack of medical support system)

Sedative-hypnotic Conversion Table Generic Name Approximate Equivalents to Diazepam 10 mg or Phenobarbital 0 mg 1 Time to Peak Plasma level (in Hours) Half-life Parent Drug (in Hours) Metabolite Activity (Maximal Half-life in Hours) Alprazolam 1 mg 1-1 ± Inactive Chlordiazepoxide mg 1-4 10 ±.4 Active (up to 10) Clonazepam 1 mg 1-4 ± Inactive Clorazepate 1 mg Variable ± 0.9 Active (up to 10) Diazepam 10 mg 1-4 ± 1 Active (up to 10) Estazolam 1 mg 0.-0. 10-4 Inactive Flurazepam 1 mg 0.-1.0 74 ± 4 Active (up to 100) Lorazepam mg -4 14 ± Inactive Oxazepam 0 mg - 8.0 ± Inactive Quazepam 10 mg 1. 9 Active (up to 7) Temazepam 1 mg. 11 ± Inactive Triazolam 0. mg 1-.9 ± 1.0 Inactive Eszopiclone 1 mg 1 Active (<parent) Zaleplon 0 mg 1 1 Inactive Zolpidem 0 mg 1. Inactive Butalbital 0 mg 1- Inactive Pentobarbital 100 mg 0.-1 1-0 Inactive Phenobarbital 0 mg 1+ -140 Inactive Meprobamate 400 mg - 10 Inactive Carisoprodol 0 mg 1- Active (see Meprobamate) Choral hydrate 0 mg 0. <1 Active (up to 94) Abbreviation: mg: milligrams 1 Withdrawal doses of diazepam or phenobarbital are those sufficient to suppress most withdrawal symptoms and may not reflect therapeutic dose equivalency. Half-life of active metabolite(s) may differ. Primary route of barbiturate elimination is renal excretion.